^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SU 14813
i
Other names: SU 14813, SU-014813, SU 014813
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer
Drug class:
FLT3 inhibitor, VEGFR inhibitor, PDGFR β inhibitor, CSF-1R inhibitor
Related drugs:
22d
Targeting WDR12 Unleashes T-Cell-Mediated Antitumor Activity in Melanoma by Destabilizing CD276. (PubMed, Adv Sci (Weinh))
In vivo, WDR12 targeting sensitizes tumors to PD-1 blockade, and combined SU14813 and anti-PD-1 therapy produces superior antitumor efficacy. These results define a WDR12-CCT7-CD276 axis that sustains immune resistance in melanoma and nominate WDR12 inhibition with PD-1 blockade as a promising therapeutic strategy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
SU 14813
Share via
